TY  - JOUR 
AU  - Standaert, David G.
AU  - Aldred, Jason
AU  - Anca-Herschkovitsch, Marieta
AU  - Bourgeois, Paul
AU  - Cubo Delgado, Esther
AU  - Davis, Thomas L.
AU  - Iansek, Robert
AU  - Kovács, Norbert
AU  - Pontieri, Francesco E.
AU  - Siddiqui, Mustafa S.
AU  - Simu, Mihaela
AU  - Bergmann, Lars
AU  - Kukreja, Pavnit
AU  - Robieson, Weining
AU  - Chaudhuri, K. Ray
PY  - 2021
SN  - 2330-1619
UR  - http://hdl.handle.net/10259/8812
AB  - Background:Levodopa-carbidopa intestinal gel (LCIG) is an established treatment for improvingmotor and some non-motor symptoms (NMS) in patients with advanced Parkinson’s disease (PD). Prospectivelong-term data in routine clinical practice are...
LA  - eng
PB  - International Parkinson and Movement Disorder Society
KW  - DUOGLOBE
KW  - Parkinson’s disease
KW  - Levodopa-carbidopa intestinal gel
KW  - Dyskinesia
KW  - Real-world data
KW  - Sistema nervioso-Enfermedades
KW  - Nervous system-Diseases
KW  - Medicina
KW  - Medicine
KW  - Neurología
KW  - Neurology
TI  - DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease
DO  - 10.1002/mdc3.13239
T2  - Movement Disorders Clinical Practice
VL  - 8
M2  - 1061
ER  -